Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road SW
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.80 | 42.20 | 0.47% |
| CAC 40 | 7,906.39 | 59.07 | 0.75% |
| DAX 40 | 25,613.54 | 202.70 | 0.80% |
| Dow JONES (US) | 52,420.35 | 58.77 | 0.11% |
| FTSE 100 | 10,684.30 | 83.03 | -0.77% |
| HKSE | 23,041.32 | 170.49 | -0.73% |
| NASDAQ | 26,449.82 | 280.44 | 1.07% |
| Nikkei 225 | 63,268.37 | 1,078.72 | 1.73% |
| NZX 50 Index | 13,680.27 | 53.66 | -0.39% |
| S&P 500 | 7,722.33 | 45.56 | 0.59% |
| S&P/ASX 200 | 8,850.10 | 40.20 | 0.46% |
| SSE Composite Index | 3,648.30 | 49.22 | -1.33% |